Thrombosis and Haemostasis, Table of Contents Thromb Haemost 1995; 74(01): 364-368DOI: 10.1055/s-0038-1642703 Symposium Low Molecular Weight Heparin Schattauer GmbH Stuttgart Effectiveness and Safety of Low Molecular Weight Heparins (LMWH) in the Prevention of Venous Thromboembolism (VTE) V V Kakkar Thrombosis Research Institute, London, UK › Author Affiliations Recommend Article Abstract PDF Download Buy Article PDF (422 kb) References References 1 Kakkar VV, Djazaeri B, Fok J, Fletcher M, Scully MF, West wick J. Low molecular weight heparin in the prophylaxis of venous thrombosis. Brit Med J 1982; 284: 375-379 2 Kakkar VV, Muraary WJ G. Efficacy and safety of low molecular weight heparin (CY216) in preventing postoperative venous thromboembolism:A cooperative study. Br J Surg 1986; 71: 788-791 3 Hirsh J, Levine M. Low molecular weight heparin. Blood 1979; 1-17 4 Fareed J, Walanga JM, Hoppensteadt D, Racanelli A, Coyne E. Chemical and biological heterogeneity in low molecular weight heparins: Implications for clinical use and standardization. Semin Thromb Hemost 1989; 15: 440-445 5 Bendetowicz AV, Pacaud E, Beguin S, Uzan A, Hemker HG. On the relationship between molecular mass and anticoagulant activity of a low molecular weight heparin. Thromb Haemost 1992; 67: 556-562 6 Béguin S, Wrelders S, Lormeau JC, Hemker HG. The mode of action of CY216 and CY222 in plasma. Thromb Haemost 1992; 67: 33-41 7 Nurmohamed MT, Rosendaal FR, Buller HR, Dekker E, Hommes DW, Vandenbroucka JP, Berret E. Low molecular weight heparin versus standard heparin in general and orthopaedic surgery: A meta-analysis. Lancet 1992; 340: 152-156 8 Leizorovicz A, Naugh MC, Chapuis FR, Samama MM, Boissel JP. Low molecular weight heparins in the prevention of perioperative thrombosis. Brit Med J 1992; 305: 913-920 9 Jorgensen LN, Wille-Jorgensen P, Hauch O. Prophylaxis of postoperative thromboembolism with low molecular weight heparins. Brit J Surg 1993; 30: 689-704 10 Hull R, Raskob G, Pineo G, Rosenbloom D. et al. A comparison of subcutaneous low molecular weight heparin with warfarin sodium for prophylaxis against deep vein thrombosis after hip or knee implantation. New Engl J Med 1993; 329: 1370-1376 11 Carter CJ, Kelton JG, Hirsh J, Cerskus AL, Santos AV, Gent M. The relationship between the haemorrhagic and antithrombotic properties of low molecular weight heparins and heparin. Blood 1982; 59: 1212-1237 12 Esquivel CO, Bergqvist D, Bjoik CG, Nilsson B. Comparison between commercial heparin, low molecular weight heparin and pentosan polyphosphate on haemostasis and platelets in vivo. Thromb Res 1982; 28: 389 13 Prevention of Fatal Postoperative Pulmonary Embolism by Low Doses of Heparin: An International Multicentre Trial. Lancet 1975; 45-51 14 Lane DA, Pejler G, Flynn AM, Thompson EA, Lindahl U. Neutralization of heparin-related saccharides by histidine-rich glycoprotein and platelet factor 4. J Biol Chem 1986; 261: 3939-3980 15 Petersen CB, Morgan WT, Blackburn MN. Histidine-rich glycoprotein modulation of the anticoagulant activity of heparin. J Biol chem 1987; 262: 7567-7575 16 Sobel M, McNeill PM, Carlson PL, Kermode JC, Adelman B, Conroy R, Marques D. Heparin inhibition of von Willebrand factor-dependent platelet function in vitro and in vivo. J Clin Invest 1991; 87: 1717-1789 17 Kakkar VV. Efficacy and safety of Clivarine and other LMWHs in general surgery: A meta-analysis. Blood Coag Fibrinol 1993; 4 Suppl (Suppl. 01) 23S-27S 18 Kakkar VV, Cohen AT, Edmondson RA, Phillips MJ. et al. Low molecular weight heparin versus standard heparin for prevention of venous thromboembolism after major abdominal surgery. Lancet 1993; 341: 259-265 19 Verstraete M. Pharmacokinetic aspects of unfracticmated and low molecular weight heparins. Dragsz 1990; 40 (04) 418-430 20 Frydman A, Bara L, Laroux Y, Woler M, Chauliaa F, Duchier J, Samama M. The antithrombotic activity and pharmacokinetics of Enoxaparin, a low molecular weight heparin, in man given single subcutaneous doses of 20 up to 80mg. J Clin Pharmacol 1988; 28: 606-608 21 Bradbrook ID, Magnani HM, Moelker HC, Morrison PJ, Robinson J, Rogers HS. et al. ORG10172 A low molecular weight heparinoid anticoagulant with a long half-life in man. Br J Pharmacol 1987; 23: 666-667 22 Drummond M, Aristides M, Davies L, Forbes C. Economic evaluation of standard heparin and Enoxaparin for prophylaxis against deep vein thrombosis in elective hip surgery. Brit J Surg 1994; 81: 1974-1976 23 Brandt A, Bergemann R, Palmer A, Kirchoff B, Kakkar VV. Cost-effectiveness analysis oflow molecular weight heparin versus unfractionated heparin in orthopaedic and general surgery. 1995 Submitted for publication
